Journal Home
Search for

Volume 73, Issue 2, Pages 184-186 (August 2009)


View previous. 19 of 44 View next.

Association between human papillomavirus and Epstein-Barr virus infections in human oral carcinogenesis

Ala-Eddin Al MoustafaabcCorresponding Author Informationemail addressemail address, Dongfeng Chend, Lina Ghabreaub, Nizar Akilb

Received 18 February 2009; accepted 21 February 2009. published online 10 April 2009.

Summary 

Infection by high-risk human papillomaviruses (HPVs) and Epstein-Barr virus (EBV) are very frequent in the adult human population, and have been associated with several human carcinomas, especially oral cancers. However, a small number of studies have examined the association between high-risk HPV and EBV in the progression of human oral cancers. Currently, the role of high-risk HPV and EBV co-infections in human oral cancers, particularly nasopharyngeal carcinomas, remain uncertain because of the limited number of investigations. This raises the question whether high-risk HPV and EBV co-infections play a significant role in the development of human nasopharyngeal carcinomas. In this paper, we propose the hypothesis that human oral normal epithelial cells, especially nasopharyngeal cells, are very susceptible to persistent HPV and EBV co-infections; therefore, high-risk HPV and EBV co-infections play an important role in the initiation of a neoplastic transformation of human oral epithelial cells. We believe that significant studies, using different cells and animal models as well as clinical samples, are necessary to answer these important questions.

a Montréal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montréal, Quebec, Canada

b Departments of Pathology and Anatomy, Faculty of Medicine, University of Aleppo, Aleppo, Syria

c Department of Oncology, McGill University, Montréal, Quebec, Canada

d Department of Gastroenterology, Daping Hospital, Third Military Medical University, Chongqing 400042, China

Corresponding Author InformationCorresponding author. Address: Montréal Center for Experimental Therapeutics in Cancer, Lady Davis Institute for Medical Research of the Sir Mortimer B. Davis-Jewish General Hospital, 3755, Ch. de la Cote Ste-Catherine, Montréal, Quebec, Canada H3T 1E2. Tel.: +1 514 340 8222x3104; fax: +1 514 340 8716.

PII: S0306-9877(09)00168-6

doi:10.1016/j.mehy.2009.02.025


View previous. 19 of 44 View next.